Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a note that publications are automatically filled in from PubMed and may not be about the study, and updated the revision to v3.3.2.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoved the government funding status disclaimer from the page, an administrative banner that does not affect study content, eligibility, locations, or user actions. No substantive changes to the study data or navigation were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedNo significant additions or deletions were detected on the page.SummaryDifference0.4%

- Check62 days agoChange DetectedCore content updated: replaces the mature T-cell/NK-cell non-Hodgkin lymphoma entry with malignant lymphoma, large B-cell, diffuse, and updates the revision/version to v3.2.0; adds a government operating-status notice. Overall meaning shifts from a previous lymphoma subtype listing to a broader large B-cell diffuse lymphoma entry and includes operational status information.SummaryDifference3%

- Check69 days agoChange DetectedNew version tag v3.1.0 added; one disease term 'Diffuse large b-cell lymphoma' removed. Overall, minimal impact on core content.SummaryDifference0.2%

- Check83 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' link.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.